RECURRENT MULTIPLE MYELOMA
Clinical trials for RECURRENT MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RECURRENT MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Two-Drug combo aims to beat back returning myeloma
Disease control Not yet recruitingThis study compares a new combination of teclistamab and pomalidomide against the standard treatment (carfilzomib, pomalidomide, and dexamethasone) for multiple myeloma that has come back after improvement. About 162 adults with relapsed or refractory myeloma will take part. The …
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Can a drug stop dangerous side effects of new myeloma therapies?
Disease control Not yet recruitingThis phase 2 trial tests whether infliximab, a drug that blocks inflammation, can prevent cytokine release syndrome (CRS) in people with relapsed or refractory multiple myeloma receiving teclistamab or talquetamab. CRS is a common and sometimes serious side effect of these treatm…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Naresh Bumma • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New targeted radiation therapy aims to improve stem cell transplants for tough myeloma
Disease control Not yet recruitingThis early-phase trial tests a new approach for high-risk multiple myeloma: a radioactive antibody that targets cancer cells, followed by a donor stem cell transplant. The antibody delivers radiation directly to myeloma cells, while chemotherapy and low-dose radiation help prepar…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for tough myeloma: Two-Drug combo takes on relapsed cancer
Disease control Not yet recruitingThis phase II trial compares a new combination of daratumumab and teclistamab against standard treatments for high-risk multiple myeloma that has relapsed or not responded to therapy. About 80 adults will be randomly assigned to either the new combo or usual care. The goal is to …
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC